Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RBN-3143 in Healthy Subjects and Atopic Dermatitis
NCT05215808Phase 1Recruiting
- Sponsor
- Ribon Therapeutics
- Start
- Mar 2022
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of RBN-3143 in atopic dermatitis (AD) (5 arms), sponsored by Ribon Therapeutics. Primary endpoint: Safety determined by Dose Limiting Toxicities at 30 days. Started Mar 2022; status: recruiting.
02
Drugs
RBN-3143
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05215808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05215808.